Welcome to our dedicated page for Sol Gel Technolg news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Technolg stock.
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of innovative dermatological drug products. The company leverages its proprietary silica-based microencapsulation technology to create topical treatments that aim to improve efficacy, reduce side effects, and enhance patient tolerability. This unique technology encapsulates active drug substances within porous silica microcapsules, forming a protective barrier between the drug and the skin while enabling controlled drug release.
Core Business and Product Portfolio
Sol-Gel operates within the niche dermatology pharmaceutical sector, addressing skin conditions such as acne vulgaris, rosacea, and other dermatological disorders. Its product portfolio includes both branded and generic topical drugs. Notably, the company has developed two FDA-approved products:
- TWYNEO®: A combination treatment for acne vulgaris in adults and pediatric patients aged nine years and older.
- EPSOLAY®: A topical treatment for inflammatory lesions of rosacea in adults.
Both products are exclusively licensed to Galderma for commercialization in the United States and to Searchlight in Canada, showcasing Sol-Gel's collaborative business model.
Proprietary Technology and Innovation
The company's silica-based microencapsulation technology is a cornerstone of its R&D efforts. This platform enables the development of novel fixed-dose combinations and enhances the tolerability of topical drugs by creating a controlled-release mechanism. This technological edge allows Sol-Gel to address unmet needs in dermatology, providing solutions that are potentially more effective and safer than currently available treatments.
Pipeline and Future Opportunities
Sol-Gel's pipeline includes several promising candidates, such as:
- SGT-610: A hedgehog pathway inhibitor in Phase 3 clinical trials for the prevention of basal cell carcinoma lesions in patients with Gorlin syndrome. This candidate has the potential to be the first-ever treatment for this indication, offering an improved safety profile compared to oral alternatives.
- SGT-210: A topical treatment under investigation for rare hyper-keratinization disorders.
The company is also exploring opportunities for generic dermatological drugs, further diversifying its revenue streams and market presence.
Business Model and Partnerships
Sol-Gel's business model combines in-house development with strategic partnerships for commercialization. By licensing its products to established pharmaceutical companies like Galderma and Searchlight, Sol-Gel benefits from their extensive marketing and distribution networks. Additionally, the company has entered agreements with Beimei Pharma for the commercialization of its products in China, Hong Kong, Macau, Taiwan, and Israel.
Competitive Landscape
Operating in the competitive dermatology pharmaceutical industry, Sol-Gel faces challenges from larger firms with greater financial and technological resources. However, its proprietary technology, focus on niche markets, and strategic partnerships provide a competitive edge. The company's emphasis on innovation and addressing unmet medical needs positions it as a significant player in its field.
Key Differentiators
- Innovative Technology: The silica-based microencapsulation platform sets Sol-Gel apart by enabling safer and more effective drug formulations.
- Collaborative Model: Licensing agreements with industry leaders like Galderma enhance commercialization potential while reducing operational risks.
- Diverse Pipeline: A mix of branded, generic, and orphan drug candidates ensures a balanced approach to market opportunities.
Conclusion
Sol-Gel Technologies Ltd. is a forward-thinking pharmaceutical company specializing in dermatological treatments. Its proprietary technology, FDA-approved products, and robust pipeline underscore its commitment to innovation and patient care. By leveraging strategic partnerships and focusing on unmet medical needs, Sol-Gel is well-positioned within the dermatology sector to deliver impactful solutions for skin diseases.
Sol-Gel Technologies (NASDAQ: SLGL) has announced the acquisition of patidegib, a hedgehog signaling pathway blocker, from PellePharm. This drug is targeted for treating Gorlin syndrome, a rare disease with no FDA-approved therapies. The acquisition is set to close around January 30, 2023, with a total upfront payment of $4.7 million and potential milestone payments totaling up to $70.7 million. The Phase 3 study for SGT-610 is expected to start in the latter half of 2023, aiming for FDA approval by the end of 2025, with projected peak sales exceeding $300 million annually.
Sol-Gel Technologies (NASDAQ: SLGL) reported Q3 2022 financial results with revenue of $0.3 million, a significant decline from $8.8 million in Q3 2021. The decreased revenue is attributed to lower sales from EPSOLAY and TWYNEO, despite improvements in prescriber adoption. Research and development expenses dropped to $2.0 million from $6.0 million year-over-year, aiding in cash management. The company reported a loss of $3.4 million, down from a profit of $1.3 million in the previous year. However, Sol-Gel's cash runway is projected to last through Q1 2024, supported by ongoing partnerships.
Sol-Gel Technologies (NASDAQ: SLGL) has appointed Michael Glezin as Vice President of Business Development. Glezin, who has over a decade of experience in in-licensing and out-licensing within multiple territories, will focus on securing new business opportunities and commercial partnerships outside the U.S. His prior experience includes a senior role at Dexcel Pharma. CEO Alon Seri-Levy emphasized that Glezin's expertise will enhance Sol-Gel's growth potential and revenue streams from its microencapsulation technology and approved drugs, TWYNEO and EPSOLAY, which are exclusively licensed to Galderma.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) reported strong prescription volumes for its products EPSOLAY and TWYNEO, indicating a favorable launch trajectory. The company received a $3.5 million milestone payment from Galderma for FDA approval of EPSOLAY, boosting revenues to $3.5 million for Q2 2022, compared to $0.9 million in the previous year. R&D expenses decreased to $2.4 million, contributing to a reduced net loss of $0.1 million compared to $8.0 million in Q2 2021. With $36.6 million in cash and securities, Sol-Gel can fund its operations through the end of 2023.
Sol-Gel Technologies (NASDAQ: SLGL) has announced that CEO Alon Seri-Levy will present a corporate update at the 2022 Jefferies Global Healthcare Conference from June 8-10, 2022, in New York, NY. The presentation will occur on June 8 at 8:30 am ET in Track 9, with additional 1:1 meetings available. Sol-Gel is focused on developing topical drug products for skin diseases, including TWYNEO® and EPSOLAY, both licensed to Galderma for U.S. commercialization. The company is also advancing early-stage candidates SGT-210, SGT-310, and SGT-510 for other dermatologic indications.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology-focused company, announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The event will feature an on-demand presentation starting May 24 at 7:00 AM EDT, along with one-on-one meetings. Sol-Gel specializes in developing topical drugs, including TWYNEO® for acne treatment and EPSOLAY for rosacea, both licensed to Galderma. The company is also advancing early-stage drug candidates for various dermatological diseases.
Sol-Gel Technologies (SLGL) announced FDA approval for EPSOLAY®, a benzoyl peroxide cream for treating inflammatory lesions of rosacea, marking their second product launch within a year. Partner Galderma is set to launch EPSOLAY this quarter, following the successful U.S. launch of TWYNEO in April, targeting acne vulgaris. Despite nominal revenue of $0 for Q1 2022, and a reported loss of $5.6 million, the company expects its cash runway to extend through the end of 2023, thanks to partnerships that are poised to enhance product availability in dermatological treatments.
Sol-Gel Technologies (NASDAQ: SLGL) announced FDA approval for EPSOLAY, a benzoyl peroxide cream (5%) for treating rosacea in adults. The exclusive commercialization rights have been granted to Galderma. Clinical trials demonstrated a nearly 70% reduction in inflammatory lesions after 12 weeks, with 50% of patients achieving clear or almost clear skin. EPSOLAY's microencapsulation technology allows for sustained drug release, enhancing efficacy and safety. The product is patent-protected until 2040, indicating strong market potential for the 16 million Americans affected by rosacea.
Sol-Gel Technologies (NASDAQ: SLGL) announced the U.S. launch of TWYNEO, the first FDA-approved topical cream combining tretinoin and benzoyl peroxide for acne treatment. Launched by partner Galderma at the American Academy of Dermatology conference on March 25-29, 2022, TWYNEO is available by prescription across major U.S. pharmacy chains. The product's microencapsulation technology allows for controlled release of its active ingredients, addressing acne in adults and pediatric patients aged nine and older.
Sol-Gel Technologies (SLGL) reported 2021 revenue of $31.3 million, a combination of $7.5 million in licensing and $23.8 million in collaboration revenue. The company achieved net income of $3.2 million or $0.14 earnings per share, compared to a loss in 2020. Following an agreement with Padagis, Sol-Gel will receive $21.5 million over 24 months, allowing it to focus on high-value drug development. The launch of TWYNEO® is set for Spring 2022, enhancing its product portfolio alongside the anticipated EPSOLAY approval.
FAQ
What is the current stock price of Sol Gel Technolg (SLGL)?
What is the market cap of Sol Gel Technolg (SLGL)?
What does Sol-Gel Technologies Ltd. specialize in?
What are Sol-Gel's FDA-approved products?
What is unique about Sol-Gel's technology?
Who are Sol-Gel's key commercialization partners?
What is SGT-610, and why is it significant?
What challenges does Sol-Gel face in its industry?
How does Sol-Gel generate revenue?
What is the significance of Sol-Gel's partnerships?
